使用抗CD20抗体利妥昔单抗成功辅助治疗顽固性获得性大疱性表皮松解症。 - Suppr

Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab.

作者信息

Schmidt Enno, Benoit Sandrine, Bröcker Eva-Bettina, Zillikens Detlef, Goebeler Matthias

机构信息

University of Würzburg, Würzburg, Germany.

出版信息

Arch Dermatol. 2006 Feb;142(2):147-50. doi: 10.1001/archderm.142.2.147.

DOI:10.1001/archderm.142.2.147

PMID:16490841

Abstract

摘要

相似文献

Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab.

Arch Dermatol. 2006 Feb;142(2):147-50. doi: 10.1001/archderm.142.2.147.

Epidermolysis bullosa acquisita following bullous pemphigoid, successfully treated with the anti-CD20 monoclonal antibody rituximab.

Dermatology. 2007;215(3):252-5. doi: 10.1159/000106585.

Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies).

Arch Dermatol. 2007 Feb;143(2):192-8. doi: 10.1001/archderm.143.2.192.

[Successful use of combined corticosteroids and rituximab in the treatment of recalcitrant epidermolysis bullosa acquisita].

Ann Dermatol Venereol. 2009 Nov;136(11):795-9. doi: 10.1016/j.annder.2009.02.007. Epub 2009 Jun 26.

Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.

J Drugs Dermatol. 2007 Jul;6(7):731-2.

Refractory epidermolysis bullosa acquisita: successful treatment with rituximab.

Clin Exp Dermatol. 2009 Dec;34(8):e979-80. doi: 10.1111/j.1365-2230.2009.03608.x.

A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita.

Br J Dermatol. 2007 Jan;156(1):194-6. doi: 10.1111/j.1365-2133.2006.07596.x.

Treatment-resistant classical epidermolysis bullosa acquisita responding to rituximab.

Br J Dermatol. 2007 Aug;157(2):417-9. doi: 10.1111/j.1365-2133.2007.08048.x. Epub 2007 Jun 26.

Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris.

Int J Dermatol. 2008 Mar;47(3):292-4. doi: 10.1111/j.1365-4632.2008.03423.x.

Rituximab in refractory autoimmune bullous diseases.

Clin Exp Dermatol. 2006 Jul;31(4):503-8. doi: 10.1111/j.1365-2230.2006.02151.x.

引用本文的文献

Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review.

J Clin Aesthet Dermatol. 2024 Jul;17(7):24-36.

Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review.

Front Immunol. 2023 Jul 12;14:1214011. doi: 10.3389/fimmu.2023.1214011. eCollection 2023.

Off-Label Uses of Rituximab in Dermatology.

Curr Dermatol Rep. 2022;11(4):209-220. doi: 10.1007/s13671-022-00375-4. Epub 2022 Oct 6.

Epidermolysis Bullosa Acquisita: The 2019 Update.

Front Med (Lausanne). 2019 Jan 10;5:362. doi: 10.3389/fmed.2018.00362. eCollection 2018.

Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Drugs. 2018 Oct;78(15):1527-1548. doi: 10.1007/s40265-018-0976-5.

Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management.

Clin Rev Allergy Immunol. 2018 Feb;54(1):26-51. doi: 10.1007/s12016-017-8633-4.

Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

F1000Res. 2017 Jan 27;6:83. doi: 10.12688/f1000research.9476.1. eCollection 2017.

Persistent autoantibody-production by intermediates between short-and long-lived plasma cells in inflamed lymph nodes of experimental epidermolysis bullosa acquisita.

PLoS One. 2013 Dec 26;8(12):e83631. doi: 10.1371/journal.pone.0083631. eCollection 2013.

Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita.

ISRN Dermatol. 2013 Jul 15;2013:812029. doi: 10.1155/2013/812029. eCollection 2013.

Rituximab for autoimmune blistering diseases: recent studies, new insights.

G Ital Dermatol Venereol. 2012 Jun;147(3):269-76.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献